Fresenius Medical Care AG (FMS) Form 6-K — May 5, 2026
Fresenius Medical Care reported Q1 2026 revenue of €4.61 BN, a 6% decrease from the prior year, primarily driven by negative foreign currency translation effects and the divestiture of non-core clinics. Net income attributable to shareholders fell 22% to €118 M, with basic EPS dropping to €0.43. The declines were partially offset by organic growth in all segments, supported by favorable U.S. reimbursement impacts and increased sales of the 5008X CAREsystem.
Key figures
- Eps
- 0.43
- Revenue
- 4612147000
- Eps Change
- -17%
- Net Income
- 164763000
- Total Debt
- 7416042000
- Revenue Yoy
- -6%
- Cash Position
- 1239145000
- Free Cash Flow
- 40000000
- ROIC
- 4.9%
- Net Leverage Ratio
- 2.6x
- Remaining Share Buyback Liability
- €67,384,000
- Total Shares Repurchased (Q1 2026)
- 9,200,400
- FME25+ Program Savings (Cumulative)
- €854,000,000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.